Table 4.
Population pharmacokinetic model of thioTEPA.
Model: CL = θ1 + θ9*(AP-57) + θ10*(ALB-43); V1 = θ2 + θ11*(TP-61); k12 = θ3; k21 = θ4, fm*= θ5; k = θ6 + θ12*(WGT-68); k34 = θ7; k43 = θ8.
Parameter | Population value (RSD)1 | Interindividual variability (%) (RSD)1 | Interoccasion variability (%) (RSD)1 |
---|---|---|---|
θ1 CL (l*h–1) | 34.0 (0.067) | 18 (0.33) | 11 (0.35) |
θ2V1 (l) | 46.9 (0.062) | 7.5 (2.1) | 19 (0.54) |
θ3k12 (h–1) | 0.304 (0.17) | ||
θ4k21 (h–1) | 0.408 (0.20) | 51 (0.60) | |
θ5 fm* (l–1) | 0.0295 (0.17) | 39 (0.37) | 32 (0.59) |
θ6k (h–1) | 0.636 (0.23) | 27 (0.67) | 32 (0.32) |
θ7 k34 (h–1) | 2.75 (0.23) | ||
θ8 k43 (h–1) | 0.851 (0.094) | 25 (058) | |
θ9 CL Alkaline phosphatase | −0.0727 (0.53) | ||
θ10 CL Serum albumin | 0.449 (0.49) | ||
θ11V1 Total protein | 0.751 (0.45) | ||
θ12k Body weight | 0.00736 (0.46) | ||
Proportional error thioTEPA (%) | 28.7 | ||
Additive error thioTEPA (µm) | 0.0209 | ||
Proportional error TEPA (%) | 22.4 |
RSD = relative standard error of estimate.